1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...

Forbes contributors publish independent expert analyses and insights. I write about finance, innovation, climate and sustainability Europe’s next wave of biotech innovation could determine how the ...